乙肝病毒表面抗原抗体与血液透析患者的生存率——一项前瞻性研究
Antibodies to hepatitis B virus surface antigen and survival of hemodialysis patients - a prospective study.
作者信息
Grzegorzewska Alicja E, Świderska Monika K, Warchoł Wojciech
机构信息
a Department of Nephrology, Transplantology and Internal Diseases , Poznan University of Medical Sciences (PUMS) , Poznań , Poland.
b Student Nephrology Research Group , PUMS , Poznań , Poland.
出版信息
Expert Rev Vaccines. 2016 Aug;15(8):1063-74. doi: 10.1080/14760584.2016.1188697. Epub 2016 May 27.
BACKGROUND
Antibodies to hepatitis B virus (HBV) surface antigen (anti-HBs) may develop in response to HBV vaccination or infection. We investigated whether anti-HBs are an independent predictor of survival in hemodialysis (HD) patients.
METHODS
A 6-year prospective study was conducted in 532 HD patients. Survival analyses were performed using the Kaplan-Meier method and the Cox proportional hazard model.
RESULTS
In HBV non-infected patients, age (P = 0.005), coronary artery disease (P = 0.002), and non-response to HBV vaccine (P = 0.008) were the independent risk factors of all-cause mortality. In HBV infected patients, the only independent predictor of all-cause mortality was coronary artery disease (P = 0.002).
CONCLUSION
The ability to produce the protective anti-HBs titer in response to HBV vaccine is a positive predictor of survival in HBV non-infected HD patients.
背景
乙型肝炎病毒（HBV）表面抗原抗体（抗-HBs）可因接种乙肝疫苗或感染乙肝病毒而产生。我们研究了抗-HBs是否是血液透析（HD）患者生存的独立预测指标。
方法
对532例HD患者进行了为期6年的前瞻性研究。采用Kaplan-Meier法和Cox比例风险模型进行生存分析。
结果
在未感染HBV的患者中，年龄（P = 0.005）、冠状动脉疾病（P = 0.002）和对乙肝疫苗无反应（P = 0.008）是全因死亡率的独立危险因素。在感染HBV的患者中，全因死亡率的唯一独立预测指标是冠状动脉疾病（P = 0.002）。
结论
对乙肝疫苗产生保护性抗-HBs滴度的能力是未感染HBV的HD患者生存的积极预测指标。
Zotero 插件